Recently, a cleavage-specific monoclonal antibody 12A12, which selectively binds to N-truncated tau (a neurotoxic 20–22 kDa NH2-derived peptide), has been found to significantly improve AD-like behavioral and neuropathological syndromes in Tg2576 animals, providing a promising immunotherapy strategy for AD [219–221]. Here, MAPT is linked to Alzheimer disease.